InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, acute myocardial infarction, and saphenous vein graft coronary intervention. It utilizes MicroNet stent platform technology to develop its products and offers solutions for various disease conditions such as stenting, embolic showers, restenosis and late stent thrombosis. The company markets its products through a network of distributors in Israel and Germany. InspireMD is headquartered in Tel Aviv, Israel
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company InspireMD Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
InspireMD Inc Company Overview
InspireMD Inc Company Snapshot
InspireMD Inc Pipeline Products and Ongoing Clinical Trials Overview
InspireMD Inc – Pipeline Analysis Overview
InspireMD Inc - Key Facts
InspireMD Inc - Major Products and Services
InspireMD Inc Pipeline Products by Development Stage
InspireMD Inc Ongoing Clinical Trials by Trial Status
InspireMD Inc Pipeline Products Overview
CGuard Embolic Prevention System
CGuard Embolic Prevention System Product Overview
CGuard Embolic Prevention System Clinical Trial
CGuard Prime
CGuard Prime Product Overview
Delivery System
Delivery System Product Overview
MGuard Drug Eluting Stent
MGuard Drug Eluting Stent Product Overview
Next Gen CGuard - 5F
Next Gen CGuard - 5F Product Overview
NGuard
NGuard Product Overview
PVGuard Peripheral
PVGuard Peripheral Product Overview
RGuard Renal
RGuard Renal Product Overview
InspireMD Inc - Key Competitors
InspireMD Inc - Key Employees
InspireMD Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
InspireMD Inc, Recent Developments
May 16, 2023: InspireMD reports first quarter 2023 financial results and provides business update
May 12, 2023: InspireMD announces May 16, 2023 as new date for first quarter 2023 results conference call and webcast
May 05, 2023: InspireMD announces May 15th as new date for first quarter 2023 financial results and corporate business update
Apr 27, 2023: InspireMD to report first quarter 2023 financial results on May 9, 2023, and provide corporate business update
Mar 30, 2023: InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
Nov 09, 2021: InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Jun 02, 2021: InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
May 11, 2021: InspireMD Announces First Quarter 2021 Financial Results
Apr 29, 2021: InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
Mar 02, 2021: InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
Table 10: CGuard Embolic Prevention System - Product Status
Table 11: CGuard Embolic Prevention System - Product Description
Table 12: CGuard Embolic Prevention System - A Multicenter, Single-arm, Pivotal Study to Evaluate the Safety and Efficacy of the CGuard Carotid Stent System When Used to Treat Symptomatic and Asymptomatic Carotid Artery Stenosis in Patients Undergoing Carotid Artery Stenting
Table 13: CGuard Embolic Prevention System - A Pivotal Study of the CGuard Carotid Stent System CARENET-III for Prevention of Stroke in Patients in the United States.
Table 14: CGuard Embolic Prevention System - Acute Stroke of Carotid Artery Bifurcation Origin Treated with Use of the Micronet-covered CGUARD Stent Under Transient Flow Reversal Linked with Thrombus Retrieval: SAFEGUARD-STROKE Study
Table 15: CGuard Embolic Prevention System - Carotid Artery Revascularization Using TransCarotid flow Reversal Cerebral Protection And CGUARD MicroNET-covered Embolic Prevention Stent System to Reduce Strokes in Patients with Symptoms or Signs of Cerebral Ischemia: TOP-GUARD Study
Table 16: CGuard Embolic Prevention System - Long-term Outcomes of MicroNet-covered Stent Routine Use for Stroke Prevention in Symptomatic and Increased-risk Asymptomatic Carotid Stenosis Patients Requiring Revascularization by Neurovascular Team Decision: PARADIGM-EXTEND
Table 17: CGuard Embolic Prevention System - OPTIMAl Endovascular Exclusion of High-risk Carotid Plaque Using the CGuard Stent in Patients with Symptoms or Signs of Carotid Stenosis-related Brain Injury: IVUS Controlled Investigator Initiated Multcentric Multi-specialty Study
Table 18: CGuard Embolic Prevention System - Prospective Observational Study of CGuard MicroNet Covered Stent System Use as a Flow Diverter in the Endovascular Exclusion of Carotid Artery Aneurysms. (CGuard Divert-and-HEAL C-HEAL)
Table 19: CGuard Embolic Prevention System - Prospective Observational Study of Procedures with MicroNet Covered Stent Use to Treat Increased Risk Lesions in Arterial Locations Beyond the Carotid Bifurcation - FLOW-Guard Study
Table 20: CGuard Prime - Product Status
Table 21: CGuard Prime - Product Description
Table 22: Delivery System - Product Status
Table 23: Delivery System - Product Description
Table 24: MGuard Drug Eluting Stent - Product Status
Table 25: MGuard Drug Eluting Stent - Product Description
Table 26: Next Gen CGuard - 5F - Product Status
Table 27: Next Gen CGuard - 5F - Product Description